LXRX
Lexicon Pharmaceuticals Inc
1.90$
-0.3%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 78.3% | 81.3% | 75.2% | 73.8% | 61.0% | 80.9% | 77.4% | 64.9% | 72.5% | 77.0% | 82.5% | 55.1% | |
| 72.0% | 79.6% | 72.9% | 71.2% | 56.3% | 8.6% | 62.0% | 46.8% | 23.9% | 9.8% | 22.3% | 18.6% | |
| 72.0% | 79.6% | 72.9% | 71.2% | 56.3% | 65.0% | 74.7% | 63.4% | 71.2% | 74.1% | 79.7% | 52.0% | |
| 0.2% | 0.1% | 1.6% | 1.1% | 2.1% | 13.5% | 0.2% | 0.0% | 0.0% | 0.4% | 1.2% | 1.3% | |
| 1.0% | 0.0% | 0.0% | 0.4% | 1.6% | 1.0% | 0.0% | – | 0.0% | 0.2% | 0.1% | 0.2% | |
| 0.2% | 3.2% | 4.1% | 4.1% | 5.6% | 3.4% | 0.1% | 0.9% | 1.1% | – | – | – | |
| 9.4% | 6.8% | 9.4% | 10.2% | 15.7% | 10.7% | 21.9% | 32.5% | 22.9% | 19.4% | 14.9% | 24.1% | |
| 11.3% | 8.1% | 11.2% | 11.9% | 17.6% | 4.7% | – | – | – | – | – | – | |
| 39.7% | 56.3% | 66.9% | 88.1% | 109.3% | 72.0% | 23.3% | 17.0% | 39.7% | 59.4% | 51.1% | 41.9% | |
| 9.5% | 18.8% | 34.6% | 28.4% | 12.9% | 15.6% | 23.0% | 16.2% | 11.9% | 13.7% | 15.2% | 11.3% | |
| 2.1% | -3.5% | -3.3% | 0.5% | -5.1% | 2.8% | 6.0% | 0.8% | 0.7% | 0.6% | 0.4% | 3.4% | |
| 2.8% | 3.0% | 11.1% | 8.9% | 4.2% | 2.9% | 2.7% | 6.7% | 5.4% | 6.3% | 5.0% | 1.7% | |
| 18.6% | 15.9% | 17.9% | 53.0% | 85.8% | 56.1% | – | – | 25.0% | 43.4% | 33.6% | 26.7% | |
| 60.3% | 43.7% | 33.1% | 11.9% | -517.9% | 28.0% | 76.7% | 83.0% | 60.3% | 40.6% | 48.9% | 58.1% | |
| -234.3% | -169.3% | -262.9% | -316.4% | -517.9% | -321.1% | -687.0% | -1,086.7% | -818.2% | -770.1% | -659.2% | -1,090.7% | |
| 16.2% | 15.8% | 21.8% | 24.1% | 37.2% | 27.9% | 54.4% | 106.4% | 85.3% | 96.4% | 107.2% | 196.3% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.